Skip to main content

Genital Wart

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Bovax Biotechnology
Bovax BiotechnologyChina - Chongqing
1 program
1
9-valent Human PapillomavirusPhase 31 trial
Active Trials
NCT06465914Active Not Recruiting9,000Est. Jul 2030

Trial Timeline

Clinical trial activity over time

2024
2025
2026
2027
2028
2029
2030
Bovax Biotechnology9-valent Human Papillomavirus

Clinical Trials (1)

Total enrollment: 9,000 patients across 1 trials

NCT06465914Bovax Biotechnology9-valent Human Papillomavirus

A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males

Start: Jul 2024Est. completion: Jul 20309,000 patients
Phase 3Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.